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LigandsThe general progression of cancer drug development involves in vitro testing followed by safety and efﬁcacy eval-
uation in clinical trials. Due to the expense of bringing candidate drugs to trials, in vitromodels of cancer cells and
tumor biology are required to screen drugs. There are many examples of drugs exhibiting cytotoxic behavior in
cancer cells in vitro but losing efﬁcacy in vivo, and in many cases, this is the result of poorly understood
chemoresistant effects conferred by the cancermicroenvironment. To address this, improvedmethods for cultur-
ing cancer cells in biomimetic scaffolds have been developed; along theway, a great deal about the nature of can-
cer cell-extracellular matrix (ECM) interactions has been discovered. These discoveries will continue to be
leveragedboth in thedevelopment of novel drugs targeting these interactions and in the fabrication of biomimet-
ic substrates for efﬁcient cancer drug screening in vitro.
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The diverse nature of cancer evinces the great variety of relevant
biochemical pathways—the loss of differentiation in cancer cells in
many ways shares functional characteristics with stem cells and devel-
opment. A number of strategies have been pursued to both prevent and
treat cancer, each relying on a different facet of the disease. Of thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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FDA, themajority are targeted toward DNA replication and repair path-
ways (e.g. alkylating agents, antimetabolites, anthracyclines, topoisom-
erase inhibitors, or mitotic inhibitors [1]). A number of recently
approved drugs are angiogenesis inhibitors [2], but to date, a drug
targeting a cancer cell's interactionswith the extracellular environment
has not been approved, despite the fact that cancer's relationship with
the extracellular matrix (ECM) has received increasing scrutiny in the
lab. Speciﬁcally, the ways in which cancer cells interact with the physi-
cal properties of the ECM, how cancer cell–ECM attachment can directly
affect treatment efﬁcacy, and the development of modern drug strate-
gies taking advantage of the cancer–ECM relationship are all gaining im-
portance. The goal of this review is to provide a comprehensive
overview of A) important breakthroughs in the understanding of phys-
ical cancer–ECM interactions in vitro, B) the increasing evidence that
these interactions can abrogate the effects of chemotherapeutic inter-
vention, and C) the current state of cancer-ECM-based drug discovery
and development, with a special focus on how basic science discoveries
have informed this pipeline.
2. Thephysical relationship between cancer cells and the extracellular
matrix in vitro
The extracellular matrix (ECM) is a highly complex ﬁbrous mesh
composed of proteins (e.g. collagen, laminin, ﬁbronectin, elastin), gly-
cosaminoglycans (e.g. hyaluronic acid, heparin), proteoglycans (e.g.
perlecan, syndecan), and sequestered growth factors. The ECM not
only plays an important role in providing support to tissues but also di-
rects a diverse set of functions in individual cells. Physical properties of
the extracellular matrix like stiffness, topography, and ligand presenta-
tion have been shown to affect a variety of cellular responses [3–5]. Ad-
hesion of cells via speciﬁc receptors, mainly integrins, to the ECM
stimulates signaling pathways that regulate survival, proliferation, mi-
gration, polarity, and differentiation [6–8]. Each of these properties of
cancer cell–ECM interaction can and have beenmodeled by researchers
in vitro (Fig. 1) in the pursuit of a more faithful mimic of the in vivo
tumormicroenvironment [9–12] As both chemical and physical charac-
teristics of the ECM inﬂuence cell behavior, and these speciﬁc properties
can be altered in cancer, a better understanding of cancer ECM compo-
sition and subsequent cellular responses are required [13–15]. Thewell-
characterized action of matrix metalloproteinases (MMPs) bearFig. 1. Tumor/cancer cell–ECM interactions in vivo that can be modeled in vitro. In the tumor micro
tumor behavior. In tumor microenvironments, the ECM tends to be stiffer, usually as a result o
topography of the ECM, as well as dictates which ligands will be accessible to the cells. Intersti
caused by enhanced angiogenesis. Cells can be exposed to three-dimensional ECM in the stroma
also subject to shear forces and cyclic strain.mentioning despite being beyond the scope of this review; examina-
tions of both in vitro basic research and MMP-centered clinical trials
can be found in several excellent reviews [16–18].
2.1. Stiffness
Matrix rigidity has been shown to inﬂuence cellular migration
[19–22], adhesion [23–25], proliferation [26–28], and differentiation
[29,30]. Cellular sensing of rigidity is a complex process integratingmul-
tiple mechanosensitive pathways [31]; thus, the use of substrates in
which rigidity can be precisely tuned to mimic that of both healthy
and cancerous tissue is important in presenting physiologically relevant
properties to cells in vitro [32].
In the context of cancer biology, ECM stiffness and cellular stiffness,
i.e. the elastic moduli of individual cells, are intertwined, as the differ-
ence between these two material properties can deﬁne the nature of
their interaction. Metastatic cancer cells have consistently been shown
to be softer than benign cells, with some cell types exhibiting stiffnesses
an order of magnitude lower than their healthy counterparts [33–36].
This could be the result of impaired keratin organization observed in a
number of cancer cell types [37], as keratin reorganization prompts a
sharp drop in individual cell stiffness [38]. This is in contrast to tumor-
associated ECM, which has been found to be generally stiffer than sur-
rounding healthy tissue [39–42]. There are a number of contributing
factors potentially at play in malignant matrix stiffening, including ﬁ-
brosis [43,44] and the increase in interstitial pressure due to tumor
growth and chaotic microvasculature [45]. Additionally, collagen net-
works have been shown to stiffen in breast cancer (BC) [46], which is
likely due to the crosslinking role of the enzyme lysyl oxidase (LOX).
LOX has been found to be upregulated in breast tumors and may play
a role in focal adhesion kinase (FAK) activation and cell-matrix adhesion
[47]. Increases in collagen network deposition and/or stiffness have
been shown to stimulate integrin signaling and cancer cell proliferation
[44,48], further reinforcing the role of substrate mechanics in cancer
progression.
There are a number of ways in which researchers can study the ef-
fects of substrate stiffness on cancer cells in vitro. The use of ECM-
based natural biomaterials like collagen gels, hyaluronic acid (HA),
and Matrigel allows for a degree of biomimicry, and each has its own
protocol for controlling stiffness. For instance, collagen gels can be at-
tached to a stiff substrate or used free-ﬂoating [48], combined withenvironment, a number of physical characteristics of the ECM can inﬂuence cancer cell or
f increased collagen crosslinking. Deposition of ECM ﬁbers like collagen contributes to the
tial pressure also rises due to poorly functioning lymphatics and chaotic microvasculature
and two-dimensional ECMupon intravasation into the circulatory system, where they are
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collagen ﬁbers [50] to control the level of elasticity felt by the cells.
Synthetic hydrogels composed of polyacrylamide (PA), polyethylene
glycol (PEG), or polydimethylsiloxane (PDMS), while not as biomimetic
as natural materials, allow for more precise control over substrate
stiffness. The stiffness of PA gels can be varied by altering the ratio of
crosslinker to monomer [19,51]. PEG gels also take advantage of
crosslinker to monomer ratios and/or photoinitiator systems to control
stiffness and have been used in 2D or 3D formats to analyze stiffness-
dependent cancer cell drug responses and migration patterns [52,53].
PDMS stiffness can be tuned by altering the ratio of base to curing
agent and has also been used to analyze cancer cell behavior in response
to different elasticities [54]. One current limitation of in vitromodels for
substrate stiffness is the fact that stiffness in vivo can be heterogeneous
over nano- and micro-scales [55], likely due to heterogeneous matrix
deposition at focal regions of tissue.2.2. Ligand accessibility
Cell adhesion and behavior have been shown to be sensitive to li-
gand presentation at the nano-scale (i.e. chemistry, density, geometry)
[56–60]. Speciﬁc ligands presented to cells in the tumor microenviron-
ment depend on the protein composition of the ECM. This composition
has been shown to control cell proliferation, migration, adhesion, and
viability [61], as well as the expression of pro-survival pathways,
allowing cells to escape drug-based treatment [62]. Tumor develop-
ment is often associated with the upregulation of different ECM pro-
teins; collagen VI expression, which correlates with tumor grade in
ovarian cancer patients, has been shown to be upregulated in drug-
resistant cancer cells, which can subsequently remodel the ECM to fur-
ther promote chemoresistance [63].
By controlling the ECM composition in vitro, important observa-
tions on the nature of ligand interactions can be made. Nanostruc-
tured, ﬂexible materials are useful for examining adhesive
properties and resultant cellular responses in cancer cells and can
be synthesized via a block copolymer micelle nanolithography
(BCML) technique, followed by transfer nanolithography onto soft
substrates, which have been extensively described in a variety of sys-
tems [64–67]. This system allows for the direct control of ligand
composition and spacing, and ongoing research is focusing on the re-
lationship between ECM ligandmotifs and chemoresistance. Directly
coating glass surfaces with biotin allows for direct conjugation of
ECM ligands; this system has been employed to better understand
the relationship between RGD (arginylglycylaspartic acid) and EGF
(epidermal growth factor) ligands. By controlling the proportion of
the two motifs, it has been shown that EGF directly affects cancer
cell focal adhesions, suggesting a connection between integrin at-
tachment and EGF receptor signaling [68].
Ligands can also be presented in a less controlled manner by
adjusting the proportion of different ECM proteins available for cancer
cells to interact with.When cells are plated in three-dimensional matri-
ces composed of the ECM protein laminin, an increase in DNAmethyla-
tion is observed, resulting in amore invasive cancer cell phenotype [69].
Hyaluronic acid hydrogels supplemented with ﬁbronectin, laminin, or
cyclic-RGD have been used to illustrate this effect, as laminin-rich gels
conveyed resistance to ERK (extracellular-signal-regulated kinase)
inhibition and ﬁbronectin-rich gels conveyed resistance to BRAF
(proto-oncogene B-rapidly accelerated ﬁbrosarcoma) inhibition [62].
The availability of collagen or ﬁbronectin in the in vitromicroenviron-
ment has also been shown to alter cancer cell stiffness, suggesting a
level of crosstalk between ligand accessibility and cell mechanics [70].
Other systems have been built that allow for combinatorial analysis of
variable ECM composition and thus ligand composition [71], showing
the ﬁrst steps towards a truly high throughput biomimetic drug screen-
ing platform.2.3. Dimensionality
While the majority of in vitro cancer cell experimentation has been
performed on two-dimensional substrates, recent advances in biomate-
rials have allowed for increasing investigation of the behavior of cancer
cells and tumors in three-dimensional scaffolds. Cancer cells can be dis-
tinguished from normal cells in three-dimensional culture by their
growth rates and morphologies; while normal cells reduce their rate of
proliferation andmaintain their spatial position,malignant cells general-
ly will grow rapidly and invade into surrounding regions [72], to the
point wheremorphology in some 3D scaffolds can predict malignant po-
tential [73]. Even among cancer cells, a morphological and behavioral
gradient exists, with more highly malignant cell lines exhibiting stellate
morphology and invasive processes compared to grape-likemorphology
in less malignant lines [74]. Clusters of cancer cells known as multicellu-
lar tumor spheroids (MCTs) cultured in these matrices can be used as
in vitro models for early tumor architecture, tumorigenic gene expres-
sion, and drug response, with invasion out of MCTs into the surrounding
3D scaffold mirroring early metastatic events [75]. Genes expressed in
these reproductions of early tumor structure have been correlated with
genes upregulated by cancer cells in vivo, validating the mimetic nature
of such models and shedding new light on difﬁcult-to-observe events
during tumorigenesis in vivo [76].
In order to study the nature of 3D ECM-cancer cell interactions, suf-
ﬁciently biomimetic substrates must be fabricated. A number of strate-
gies have been pursued, including the use of the 3D scaffold Matrigel
[75], a basementmembrane preparation extracted frommouse sarcoma
cells in vitro. 3D scaffolds composed of collagen type I have been used to
present stiffness gradients to cancer cells in vitro, allowing for the obser-
vation that cancer cells inﬁltrate more extensively into soft 300 Pa re-
gions than into stiffer 1.2 or 6.0 kPa regions [77]. Distinctly different
phenotypes of cancer cell invasion have been observed on 2D and 3D
substrates, with cells in unconﬁned lines exhibiting ‘push-and-pull’ be-
havior characteristic of mesenchymal invasion, and cells in conﬁned
microchannels moving in an amoeboid-like sliding fashion [78].
Three-dimensional silk sponges have also been used to analyze cancer
cell behavior in vitro, with signiﬁcant differences observed in the ex-
pression of angiogenic factors compared to two-dimensional substrates
[79]. Controlled comparisons between 2D and 3D substrates have also
been performed with ﬁbronectin matrices, allowing for the observation
that integrin binding andMT1-MMP activity are required in two dimen-
sions, but not in three, illustrating the purported switch from mesen-
chymal to amoeboid cancer invasion [80]. Pseudo-3D substrates
sandwiching cancer cells in between two 2D substrates allow for precise
control over ligand presentation,making detailed analysis of focal adhe-
sion complexes and migration speed possible [81]. While the ﬁeld has
recognized that 3D scaffolds generally present a more biomimetic envi-
ronment necessary for modeling cancer cell–ECM interactions and
screening cancer cell–drug outcomes, 2D substrates have not lost all of
their usefulness. In vivo, several cancer-relevant microenvironments
are better modeled by 2D substrates, most notably the boundary be-
tween ECM and the circulatory system, but also including any 2D inter-
face in which a cell will preferentially bind to a ﬂat surface.
2.4. Topography
Surface topography refers to the nanometer or micrometer-scale
orientation of ECM components, includingﬁbrils and other supramolec-
ular structural patterns [82,83]. These patterns have been shown to
guide cancer cell migration in the tumor microenvironment, as analysis
of breast cancer explants shows that tumor cells and cancer-associated
stromal cells migrate along reassembled collagen ﬁber ‘highways’
exhibiting macroscopic topography [84]. Changes in the native mesh-
like topography of collagen ECM into radially aligned ﬁbers have been
observed in vivo [85], and in vitro experimentation has conﬁrmed that
outwardly radiating collagen ﬁber patterns can promote invasive
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ulated that ECM topography is linked to intracellular signaling in cancer
cells, likely through the physical arrangement of key integrin receptors
and focal adhesions [87]. ECMporosity, often represented as the average
cross-sectional diameter of the gaps in the ﬁbers comprising the ECM, is
another formof topography that plays a role in cancermigration and in-
vasion [88]. When matrix pore size is smaller than the width of the cell,
ECM degradation is triggered in order to alter the matrix topography,
thereby allowing invasion and migration [89]. Like other forms of to-
pography, porosity is a direct result of patterns in ECM protein deposi-
tion, and thus has a great deal of overlap with studies examining
ligand accessibility as a function of protein deposition [50,90].2.5. ‘Outside-in’ forces: Interstitial ﬂuid pressure, cyclic strain and shear
stress
The nature of forces that act upon cancer cells, or ‘outside-in’ forces,
is also altered compared to healthy tissue. Interstitial ﬂuid pressure
(IFP) in the tumor microenvironment, which is predictive of patient
outcome [91] (although conﬂicting results addressing whether in-
creased IFP is associatedwith increased or decreased long-term survival
have been reported, perhaps due to tissue type [91,92]), can be at least
an order of magnitude higher than normal tissue due to abnormal mi-
crovasculature and poorly functioning lymphatics [45]. Individual can-
cer cells have been exposed to different levels of hydrostatic pressure
in the lab, leading to the discovery that increased interstitial ﬂuid pres-
sure in vitro is sufﬁcient to alter angiogenic gene expression, a key reg-
ulator of the chaotic microvasculature responsible for aberrant IFP
in vivo [93,94], with certain cell lines displaying an increased sensitivity
to chemotherapeutic drugs while exposed to pathological IFP [92], sug-
gesting that the physical barrier to drug penetration is the driving factor
in IFP-induced chemoresistance [95]. Collagen gels under volumetric
compaction have also been used to mimic increased IFP [96] and moni-
tor subsequent changes in signaling pathways.
Shear stress, imposed onto cancer cells during intravasation into the
circulatory system after escaping the tumormicroenvironment, is anoth-
er example of a physiological force acting on cancer cells [97]. During this
process, invasive cancer cells must adhere to vessel walls; otherwise,
they will continue to recirculate and be susceptible to death by shear
stress [98]. This processmust bemore closely examined to better under-
standwhy somany intravasating cells fail to extravasate, a phenomenon
thought to contribute to the aggressive nature of cancer cells that survive
the circulatory system [99]. To mimic these conditions in vitro, cancer
cells can be plated onto ﬂat substrates and spun at 60 rotations per min-
ute [98]. Microﬂuidic devices and Darcy ﬂow chambers have been used
extensively to provide both shear stress and chemoattractant gradients,
revealing different patterns of cancer cell migration in response to differ-
ent magnitudes of shear force [100,101]. Cone and plate viscometers
have also been used to demonstrate that shear stress can affect the sen-
sitivity of circulating cancer cells to drug treatment [102].
The cyclic forces present in the circulatory system, which have his-
torically been an important focus of research due to the strong role of
angiogenesis in tumor growth, have also been shown to contribute to
mechanosensitive processes in cancer cells. Tumor-derived endothelial
cells have been examined under 10% uniaxial cyclic strain and found to
exhibit aberrant Rho-mediated mechanosensitivity, likely due to
reprogramming caused by exposure to the tumor microenvironment
[103].
Taken together, it is clear that there are awide variety of interactions
and forces that cancer cells experience in vivo. Recently, an increasing
number of groups are taking advantage of this knowledge and applying
in vivo principles to the engineering design of in vitro scaffolds and sys-
tems. Ultimately, near-perfect reconstruction of these in vivo conditions
will allow researchers to more accurately conceive, design, and test
strategies for treating cancer. However, due to the current use of less-than-ideal materials, we are learning more about the unforeseen out-
comes of chemotherapeutic treatment in vivo.
3. Evidence for the ECM altering drug treatment
There are multiple ways in which a cancer cell or tumor can obtain
resistance to drug treatment, including genemutations, gene ampliﬁca-
tion, or epigenetic alterations that impact how cells interact with vari-
ous drug compounds [104]. Several types of cancer cells have been
shown to utilize their interactions with the surrounding environment
to acquire drug resistance, either within the primary tumor (e.g. multi-
ple myeloma cells within the bone marrow), or within the context of
disseminating metastases to distant organs (e.g. metastasis of breast
or prostate cancer cells to bone) [105–110]. These interactions can be
loosely grouped into physical barriers to treatment (hypoxia, pH, and
interstitial ﬂuid pressure) and cell-adhesion-based drug resistance
(ECM organization and protective ligand binding) (Fig. 2).
3.1. Physical barriers to treatment
Inmany cases, drug delivery in the interstitial spaces in and around a
tumor relies on diffusion and pressure-driven convection [111]. As a re-
sult of this, cancer cell-driven remodeling of the ECM provides the sim-
plest resistance to treatment in the form of physical barriers that delay
or abrogate drug delivery [112]; indeed, most anticancer drugs show
limited penetration into solid tumors [104,113]. A number of strategies
have been proposed to mitigate the barrier-like effects of the ECM in
cancer drug delivery [95].
The tumormicroenvironment is extremely heterogeneous, with gra-
dients in the degree of hypoxia, pH, and ECM composition, all of which
can inﬂuence the efﬁcacy of drug treatment for several independent
reasons [104]. Hypoxia results from the limited vasculature supply to
the interior of the tumor, causing cells to proliferate at varying rates
[114,115]. Many chemotherapeutic drugs aremost effective on prolifer-
ating cells, allowing quiescent cells in the interior to evade treatment
[116]. Hypoxia can also induce the activation of cell survival or pro-
angiogenic genes, leading to certain populations of cells that become
drug-resistant [117,118]. Additionally, drugs that rely on an oxygen-
based free-radical mechanism cannot function on cells in a hypoxic
(i.e. oxygen low) environment [119]. pH is also low in the extracellular
space of hypoxic tumors, causingweakly basic drugs to become proton-
ated, hindering their ability to cross the cell membrane [120].
Due to the lack of a fully functional vasculature system, ﬂuid cannot
be properly removed from the tumor through lymphatic vessels; there-
fore, IFP is often higher in tumors than in healthy tissues. This increased
pressure inhibits the convection ofmacromolecules into the tissue [121,
122]. Composition and organization of the tumor ECM can also deter-
mine whether drugs can penetrate into the tumor. For example, colla-
gen, which is often upregulated in tumor microenvironments [63], has
been shown to contribute to drug transport resistance in the interstitial
space, possibly in conjunctionwith GAGbinding [121]. In vitro studies of
breast cancer cells in 3D collagen matrices revealed that cells in softer
regions were more susceptible to paclitaxel treatment compared to
those in stiffer regions, suggesting that tissue stiffness barriers can pro-
vide a degree of chemoprotection [77]. Organized protein structures
and tightly packed tumors can also inhibit drug penetration [121,123].
Additionally, in certain types of mucinous cancers, an upregulation in
mucin production provides individual cells with a physical barrier
against drug treatment. This mucous layer makes the cells measurably
stiffer and reduces the cytotoxic effects of applied chemotherapeutic
agents [124].
3.2. Adhesion-conferred drug resistance
Adhesion to the ECM and other cells has been shown to confer
chemoresistance to cancer cells through the activation of various pro-
Fig. 2. ECM-conferred barriers to treatment. A) Hypoxic conditions due to poor vascularization of the tumor result in poor proliferation of cells in the interior. As many chemotherapuetic
drugs target proliferating cells, more quiescent cells can survive treatment. B)Waste products from the rapidly dividing cancer cells contribute to low pH in the tumormicroenvironment,
which can protonate weakly basic drugs, preventing their passage through the cell membrane. C) Interstitial ﬂuid pressure is higher in tumors, providing a physical barrier to drug diffu-
sion. D) Tumor-directed, highly organized ECM structures inhibit drug penetration. E) The binding of certain integrins to the ECM conveys chemoresistance by activating pro-survival
pathways.
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Akt, p53MAPK, ERK/MAPK, and Rho/ROCK have been shown to be acti-
vated upon binding to the ECM, and have thus become a major focus of
anticancer therapies [127–131].
Inmultiplemyeloma(MM), themalignantplasmacells in thebonemarrow
attach to stromal elements using several adhesion receptors, directly affecting
their proliferation and survival, speciﬁcally in response to chemotherapeutic
agents such as glucocorticoids (e.g. prednisone, dexamethasone), alkylating
agents (melphalane), Velcade™, Thalidomide™ and imatinib mesylate
(Gleevec™) [110,132–138]. Despite conventional high-dose therapies and
novel treatments, MM remains an incurable disease as almost all patients re-
lapse anddevelop some formof drug resistance [132,139]. Even in early stages,
when themalignant cellsmaynot harbor genetic lesions that could confer con-
stitutive drug resistance, the epigenetic protection provided by the stromalmi-
croenvironment may enable some cells to survive within the bone marrow.
This sub-clinical periodmay endure long enough for the development of addi-
tional genetic events that may be required for the emergence of clinical resis-
tance and relapse of the MM tumor population after an apparent clinical
remission. Integrin-mediated adhesion has been described in several MM cell
lines in vitro, as well as in MM cells from patients. Both culturedMM cell lines
and patient-derived MM cells adhere to vitronectin and ﬁbronectin via the
αvβ3 integrin, or to VCAM-1 via the α4β1 integrin [140–142]. β1 integrin-
mediated adhesion ofMM cells to ﬁbronectin confers protection against drug-
induced apoptosis, and triggers NFκB-dependent transcription and secretion
of IL-6, amajorMMgrowth and survival factor [143]. Additionally, hyaluronan,
acting via the cell surface receptor CD44, has been shown to confer survival
against IL-6 starvation or dexamethasone-induced apoptosis of human MM
cells [144,145].
In breast cancer, clinical prognosis in patients is tightly linked to spe-
ciﬁc gene expression proﬁles, many of which are dominated by genes
controlling ECM expression [146]. For instance, resistance to chemo-
therapeutic agents 5-ﬂuorouracil, epirubicin, and cyclophosphamide
are dependent on the protein composition of the stromal ECM [147].
Several studies have shown that BC cell adhesion to the ECM plays an
important role in cancer cell survival post-chemotherapy treatment,
identifying speciﬁc targets such as collagen [148,149], HA [150,151],
and ﬁbulin-1 [152]. An examination of many BC cells has indicated
that they display diverse alterations in the expression of different
integrins, including α6β4, α6β1, αvβ3, as well as the Thomsen–
Friedenreich antigen (TF-Ag) and E-cadherin [107,108,153]. In vitro,
3D hydrogels containing laminin or ﬁbronectin were found to convey
chemoresistance to ERK inhibition or BRAF inhibition, respectively, fur-
ther illustrating the importance of cell–ECM protective adhesion [62].4. ECM-based cancer treatments
Most conventional chemotherapeutic interventions available today
rely on inhibiting cancer cell proliferation.While this is an important as-
pect of the disease to target, most patients ultimately die from theirme-
tastases, not their primary tumors. Thus, there is a pressing need for
novel interventions that can prevent the further dissemination of cancer
cells after treatment. As ECM interactions play an important role in can-
cer cell survival and behavior, ECM-targeted therapies provide a prom-
ising approach to this need, either in preventing ECM-conferred
chemoresistance or by altering the extracellular environment such
that current therapies can overcome physical treatment limits. Many
ECM-targeted chemotherapeutic drugs have been developed that at-
tempt to inhibit speciﬁc integrin interactions, matrix metalloproteinase
(MMP) activity, or the synthesis/degradation of the ECM, all of which
will be described in the following sections.
4.1. Integrin-targeted drugs
Interventions that target speciﬁc integrin interactions aim at
preventing protective downstream signaling effects conferred by the li-
gation of certain receptors (see Table 1). ATN-161 is a noncompetitive
inhibitor of the ﬁbronectin PHSRN sequence (the synergy sequence
that enhances RGD binding) and is unique in that it does not block
integrin-dependent adhesion, but rather targets downstream signaling
via the α5β1 and αvβ3 integrins [154–156]. When used in combination
with traditional chemotherapy, ATN-161 reduced tumor cell prolifera-
tion and improved survival in a colon cancer model due to its anti-
angiogenic and anti-pro-survival properties [155]. In patients with ad-
vanced solid tumors, one third of patients exhibited prolonged stable
disease [157], and further phase II studies are currently beingperformed
[158]. Also targeting theαvβ3 integrin is Etaracizumab (Abergrin/MEDI-
522, a variant of previous Vitaxin/MEDI-523), a humanizedmonoclonal
antibody engineered from LM609.While preclinical studies for this drug
were promising, phase II studies with patients exhibiting stage IV met-
astatic melanoma showed no clinical improvement [159].
Other integrin-targeted inhibitors have also attempted to target ad-
hesions promoting tumor-induced angiogenesis and cell survival. First
described by the Kessler group, Cilengitide, a cyclic-RGD pentapeptide,
aimed at inhibiting invasive, pro-angiogenic endothelial cells from
binding to theαVβ3 integrin, thereby inducing apoptosis and hindering
cell migration [160]. In glioblastoma patients, this drug aimed to inhibit
bothαvβ3 andαvβ5, but after strong phase II trials, fell short in phase III
Table 1
Examples of integrin-targeted chemotherapeutic drugs.
Drug Targeted integrin(s) Clinical trial
state†
Cilengitide αvβ5 /αvβ3/α5β1/αIIbβ3 Phase III
ATN-161 α5β1/αvβ3 Phase II
Etaracizumab (Abegrin, MEDI-522)⁎ αvβ3 Phase II
Intetumumab (CNTO 95) αv Phase II
Volociximab (M200) α5β1 Phase II
E7820 α2 Phase II
17E6 (EMD 525797) αv Phase II
Abituzumab (EMD 525797) αv Phase I/II
SC-68448 αvβ3/αIIbβ3 Phase I
GLPG 0187 αvβ1/αvβ3/αvβ5/αvβ6/ α5β1 Phase I
Abciximab (ReoPro, C7E3)⁎⁎ [207] αIIbβ3/αvβ3/αMβ2 Pre-clinical
S137 and S247 αvβ3 Pre-clinical
SB 265123 [178] αvβ5 /αvβ3 Pre-clinical
SM256 [208] αvβ3 Pre-clinical
SD983 [208] αvβ3 Pre-clinical
SCH221153 [209] αvβ5 /αvβ3 Pre-clinical
References are indicated for drugs not mentioned in the text.
⁎ Derived from Vitaxin/MEDI-523.
⁎⁎ Currently on the market for acute coronary syndrome.
† Ongoing, or last reported highest-level state.
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antibody to the αv integrin, unfortunately showed a decrease in both
progression-free survival and overall survival in phase II trials of meta-
static castration-resistance prostate cancer [162].
Still, there aremultiple promising interventions currently undergoing
clinical trials. Volociximab, anα5β1 inhibiting antibody, has completed a
phase Ib safety and pharmacokinetic study, in combination with
carboplatin and paclitaxel, for advanced non-small-cell lung cancer
[163]. An αv-targeting monoclonal antibody, Abituzumab (EMD
525797), has also shown promise in a randomized phase I/II POSEIDON
trial when combined with Cetuximab and Irinotecan in KRAS wild-type
metastatic colorectal cancer [164]. While the progression-free survival
target was not met, patients with tumors exhibiting high αvβ6 expres-
sion beneﬁted from the treatment [164]. In preclinical trials, S137 and
S247, small RGD-peptidomimetic antagonists, were able to inhibit lung
metastasis in mice [12,165]. Phase I studies have been completed in pa-
tients with advanced malignancies using E7820, an anti-angiogenic oral
inhibitor of integrinα2 expression, and it is currently under investigation
in phase II trials [166].
Human speciﬁc antibody 17E6 (EMD 525797) has been shown to
block in vivo tumor growth of xenografts expressingαvβ3 in 6 different
human melanomas and 5 carcinomas, but did not affect αvβ3-negative
tumors. Furthermore, the effect was determined to be directly related
to anti-tumor activity and not due to anti-angiogenic activity of αv–
integrin antagonists [167]. Currently, this drug is under investigation
in phase II clinical trials [168]. Another oral compound in Phase I clinical
trials is SC-68448, an RGD-peptidomimietic antagonist. In preclinical
studies, this compound inhibited rat Leydig cell tumor growth in mice
byup to 80% and completely blocked thedevelopment of hypercalcemia
[169,170]. Another drug targeting RGD integrins is GLPG 0187, which
inhibitsαvβ1,αvβ3,αvβ5,αvβ6 andα5β1, and is currently in phase Ib tri-
als [171].4.2. Drugs targeting ECM synthesis and degradation
Other ECM-based approaches include drugs targeting ECM synthesis
via cytokine inhibitors (i.e. TGF-β inhibitors) and drugs targeting ECM
degradation (i.e. MMP and proteinase inhibitors). TGF-β-targeting
drugs hinder TGF-β-promoted secretion and processing of ECM pro-
teins, such as collagen and ﬁbronectin [172]. Fresolimumab (GC1008)
is one such example; however, few clinical effects were seen in phase
I trials [173–177]. As this subset of drugs is cytokine-based, the topicwill not be covered here in detail, but can be found reviewed excellently
elsewhere [178].
MMP inhibitorsmake up a largemajority of ECM-targeted therapeu-
tic approaches and are reviewed elsewhere [178]. Despite early failures
[18], they remain a promising set of drugs due to their potential ability
to hinder extravasation of tumor cells into different tissues during early
stages of cancer progression. Endostar, a novel recombinant human
endostatin, has shown promising results in a variety of trials. While
the mechanism of action remains unclear, one study suggests that it
acts by suppressing activity of MMPs-2 and -9 [179]. For the treatment
of osteosarcoma patients, it showed an enhancement in event-free sur-
vival and decreased occurrence and progression ofmetastases [180]. For
non-small-cell lung cancer in phase III trials, Endostar, in combination
with platinum-based chemotherapy, resulted in signiﬁcant clinical and
survival beneﬁts [181].
Heparanase, an enzyme responsible for degrading and remodeling
the ECM, has been shown to be upregulated in multiple tumor types
and in conjunction with distant metastases [182], making its inhibition
an attractive target [61]. Adjuvant heparanase inhibitor PI-88 therapy
for the treatment of hepatocellular carcinoma has shown positive re-
sults in phase II trials, with a 13% increase in recurrence-free rate and
a postponement in time to recurrence of 78% [183]. Proteoglycans are
also a potential target as these molecules can affect angiogenesis and
cancer growth [184], and it has been shown that by inhibiting the gly-
cosaminoglycan (GAG) component using 5-hexyl-2′-deoxyuridine
(HUdR), GAG incorporation can be reduced. When intracardially
transplanted tumor cells were treated with HUdR in mice, the number
of metastatic nodules were decreased in an organ-speciﬁc manner
[185].
4.3. Drugs targeting physical barriers to chemotherapy
Asmentioned earlier, onemajor obstacle in effective drug delivery is
the physical constraints imposed by the tumor microenvironment.
Thus, combining cancer cell-killing drugs with ECM-degrading drugs
could prove to be an effective strategy. In preclinical studies of high
prostate PC3 tumors in mice, PEGPH20, a pegylated variant of the HA-
degrading enzyme rHuPH20, when delivered in combination with che-
motherapy (Docetaxel and Liposomal Doxorubicin), induced an anti-
tumor response, inhibiting growth by 70% [186]. Effective ECM-
remodeling was observed through decreased tumor IFP and water con-
tent, decompressed tumor vessels, and increased tumor vascular area,
all of which likely enhance drug perfusion [186]. Other methods to re-
duce IFP, e.g. collagenase [187] and Paclitaxel pretreatment [188],
have been explored, resulting in enhanced uptake of small molecules.
Hypoxia can be addressed with the use of nontoxic prodrugs that
become activated under hypoxic conditions. One such example,
Tirapazamine (SR-4233), a potent and selective killer of hypoxic cells
[189], has been examined in combinatorial treatments. While earlier
phase III trials showed promising results [190], a successive trial failed
to produce positive outcomes [191]; confounding results could be due
to the reduced ability of the drug to penetrate the tumor [192].
In order to overcome the acidic tumor microenvironment, raising
the local pH with small molecules or creating pH-sensitive nanodrugs
have been explored. By raising endosomal pH with various agents, up-
take of the basic drugs doxorubicin and mitoxantrone is enhanced, im-
proving their potential therapeutic effectiveness [193]. Ionizable pH-
sensitive drug delivery systems, nanosystems containing acid-labile
chemical bonds, and gas-generating pH-sensitive nanosystems are
promisingnew techniques being explored toharness the inherent prop-
erties of the acidic interstitial space [194].
4.4. Matrix-based tumor immune therapy
One recent and exciting area of exploration has been the develop-
ment of speciﬁc matrix molecules to target the activation of anti-
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therapy (ACT) aims to treat cancer with ex vivo generated T lympho-
cytes [195], and thus requires large numbers of activated T cells. In
vivo, T cells are activated upon binding to speciﬁc ligands on the surface
of antigen presenting cells [196]. To activate T cells in vitro, artiﬁcial
antigen presentation has been developed [197]. A number of strategies
to optimize this process exist, including identiﬁcation of the required li-
gand density for T cell activation [198] and the presentation of anti-CD3
monoclonal antibodies in synthetic nanoarrays for control over T cell
activation and subsequent expression of desired cellular responses
[199]. Future research in this vein will focus on the optimization of
high throughput T cell activation and expansion, most likely in parallel
withmicroﬂuidic systems capable of mimicking the 3D interactions be-
tween T cells and synthetic antigen presenting cells [200], with the ulti-
mate goal of treating cancer cells in vivo with T cells that have been
prepared ex vivo. This strategy can be employed in conjunction with
bioengineered growth factors that target the cancer ECM with super-
afﬁnity, allowing for more complete control over the regions to which
cancer cells or immune cells attach [201].
5. Future outlook and conclusions
The phenomenon whereby malignant cells reach protective niches
in the body and subsequently acquire resistance to chemotherapy via
speciﬁc, adhesion-mediated signaling processes is still poorly character-
ized at the molecular level, but understanding this process could be the
key to discovering why chemotherapy fails to provide a long-term cure
in many cases. Due to the ubiquitous nature of the ECM in healthy
tissue, it is of great importance to consider the speciﬁcity of ECM-
targeted drugs, as off-target effects could prove detrimental to the
body. Adverse bleeding events are associated with the use of αIIbβ3 an-
tagonists, as they can also alter platelet response [202]. Therefore, the
goal of systemic administration should be to enhance cancer cell-
directed recognition.
The primary obstacle in interpreting the limited data available on
adhesion-dependent drug resistance arises from the enormousmolecular
complexity of the cellular adhesive environment, making it very difﬁcult
to identify the speciﬁc epitopes responsible for protective effects.
Moreover, studies in recent years have shown that adhesion-mediated
signaling is affected not only by the chemical nature of the adhesive envi-
ronment but also by multiple physical features of the matrix, including
the spatial patterning of the adhesive epitopes available for cell binding,
the topography of the surface and the rigidity of the substrate [203]. Ad-
ditionally, as the tumor microenvironment has been put into the spot-
light as a major mediator of cancer cell fate, the need for a proper 3D
model has arisen, inwhich cell–cell, cell–matrix and organizational prop-
erties can all be precisely controlled. To do this, the ECM microenviron-
ment for each diverse cancer type must be precisely determined. A
novel approach aimed at controlling and deﬁning the adhesive mecha-
nisms underlying protective signaling and metastasis in cancer cells in
3D, and subsequently altering these adhesions to confer chemosensitivity
to resistant cells, is of great importance and need.
New approaches to leveraging the relationship between cancer cells
and the ECM have emerged very recently with the experimental im-
plantation of cancer ‘traps’—synthetic substrates designed to encourage
cancer cells to enter but not leave [204]. These devices can be used as di-
agnostic tools to identify the presence of circulating tumor cells, but also
have the potential for removal of invasive tumor cells from the body by
simply out-‘competing’ tumor niches for circulating cancer cells.
Recent observations of the relationship between cell–ECM adhesion
and malignant phenotypes suggest that simple, low-cost, label-free,
image-analysis-based characterization of adhesion signatures may play
a role in clinical diagnostics [205,206]. The continued development of
3D perfusion systems that accurately recapitulate the force basis of can-
cer cell/tumor ECM interactions will play a key role in streamlining the
drug discovery process considering the sometimes major differences indrug efﬁcacy on 2D and 3D substrates. As the transition to high through-
put cell culture and image analysis techniques led to a new age in drug
discovery, the development of high throughput 3D ECM systems in the
coming decade will prove ﬁnancially valuable by drastically lowering
the rate of false positives. In many cases combinatorial drug treatments
have been found to be more effective against cancer than single drugs,
and thus eliminating false positives from these cocktails will only en-
hance the efﬁciency of combinatorial testing.
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